Radiation Oncology

Table 3 Multivariate analysis of factors affecting intracranial PFS and OS in the patients

From: Therapeutic effect of whole brain radiotherapy on advanced NSCLC between EGFR TKI-naïve and TKI-resistant

Factors	Intracranial PFS			OS
Factors	HR	95%CI	p	HR	95%CI	p
All patients
Gender	1.10	0.50–2.41	0.82	0.67	0.33–1.36	0.27
Smoking	1.12	0.53–2.38	0.77	0.84	0.44–1.63	0.61
Age	0.99	0.65–1.52	0.97	1.40	0.33–1.36	0.11
Histology	0.82	0.54–1.23	0.33	1.40	0.93–2.13	0.11
KPS	0.90	0.58–1.40	0.63	0.97	0.65–1.46	0.88
Number of BM	0.89	0.56–1.41	0.61	0.88	0.57–1.35	0.55
Extracranial metastases	0.96	0.53–1.74	0.89	1.15	0.66–2.01	0.63
Primary disease control	0.10	0.93–2.16	0.10	0.92	0.61–1.38	0.68
Patients with Lung-molGPA 0–2
Gender	1.04	0.52–2.09	0.91	1.00	0.44–2.27	1.00
Smoking	0.82	0.40–1.68	0.59	0.98	0.43–2.20	0.95
Age	0.85	0.52–2.09	0.57	1.32	0.75–2.30	0.33
Histology	0.91	0.52–1.56	0.72	0.65	0.37–1.14	0.13
KPS	0.61	0.32–1.15	0.13	1.38	0.76–2.50	0.30
Number of BM	0.79	0.47–1.33	0.38	1.26	0.74–2.15	0.40
Extracranial metastases	0.64	0.37–1.11	0.11	1.06	0.58–1.93	0.86
Primary disease control	1.39	0.83–2.32	0.21	0.88	0.49–1.59	0.67
Patients with Lung-molGPA 2.5–4
Gender	1.11	0.66–1.85	0.70	0.81	0.50–1.31	0.39
Smoking	1.07	0.65–1.75	0.80	0.89	0.56–1.42	0.63
Age	1.07	0.77–1.48	0.70	1.49	1.09–2.05	0.01
Histology	0.79	0.58–1.09	0.15	1.12	0.81–1.54	0.51
KPS	1.02	0.74–1.39	0.93	1.06	0.78–1.43	0.73
Number of BM	0.97	0.71–1.34	0.86	0.98	0.72–1.34	0.91
Extracranial metastases	1.19	0.87–1.64	0.28	1.40	1.01–1.93	0.04
Primary disease control	1.37	0.10–1.89	0.05	1.04	0.76–1.42	0.81

Abbreviations: PFS progression-free survival, OS overall survival, HR hazard ratio, CI confidence interval, KPS Karnofsky Performance Status, BM brain metastasis, Lung-molGPA, Lung Cancer Molecular Markers Graded Prognostic Assessment

Back to article page

ISSN: 1748-717X

Contact us

General enquiries: journalsubmissions@springernature.com